Intravascular Mesenchymal Stromal/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines

Moll, Guido; Ankrum, James A.; Kamhieh‐Milz, Julian; Bieback, Karen; Ringdén, Olle; Volk, Hans‐Dieter; Geißler, Sven; Reinke, Petra

doi:10.1016/j.molmed.2018.12.006

reviewTrends in Molecular MedicineJan 30, 2019HYBRID OA

Intravascular Mesenchymal Stromal/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines

GMGuido Moll JAJames A. Ankrum JKJulian Kamhieh‐Milz KBKaren Bieback OROlle Ringdén

Humboldt-Universität zu Berlin · Berlin Institute of Health at Charité - Universitätsmedizin Berlin · +9 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

Intravascular infusion is the most popular route for therapeutic multipotent mesenchymal stromal/stem cell (MSC) delivery in hundreds of clinical trials. Meta-analysis has demonstrated that bone marrow MSC infusion is safe. It is not clear if this also applies to diverse new cell products derived from other sources, such as adipose and perinatal tissues. Different MSC products display varying levels of highly procoagulant tissue factor (TF) and may adversely trigger the instant blood-mediated inflammatory reaction (IBMIR). Suitable strategies for assessing and controlling hemocompatibility and optimized cell delivery are crucial for the development of safer and more effective MSC therapies.

Citation impact

487

total citations

FWCI: 41.25
Percentile: 100%
References: 100

Citations per year

Authors

8

Topics & keywords

Topics

Keywords

Mesenchymal stem cell
Medicine
Adipose tissue
Stem cell
Clinical trial
Bone marrow
Cell therapy
Stromal vascular fraction

No related works found for this paper.